US-based packaging company Silgan Holdings is considering a possible acquisition of German medical packaging manufacturer Gerresheimer, reported Reuters.
Sources indicate that Silgan is working with advisers on a proposal that may value Gerresheimer at €41 ($47.22) per share.
However, they emphasised that it is not yet certain whether a formal bid will be made or if any deal will be finalised.
Gerresheimer declined to respond when asked for comment, and Silgan did not provide an immediate response.
Gerresheimer has faced significant challenges in recent months.
The company’s market capitalisation currently stands at €600m ($694m), with its share price having dropped more than 80% from its highs in 2023 and falling by 37% since the beginning of this year.
Late last month, Gerresheimer announced that Germany’s financial regulator BaFin was expanding its examination of the company’s financial statements.
This development comes as the business continues to contend with accounting issues and falling share values.
Discussions between Gerresheimer and private equity investors about a potential sale took place last year but concluded without agreement.
For the fourth quarter of 2025, Silgan reported net income of $18.2m, down from $45.1m in the same period of 2024.
Its full-year net income for 2025 rose to $288.4m from $276.4m in 2024.
Silgan has projected adjusted net income per diluted share to range from $3.7 to $3.9 for 2026, a modest rise from its midpoint adjusted figure of $3.72 for 2025.
In the previous year, Silgan completed its acquisition of Weener Plastics, a Dutch dispensing solutions provider for the personal care, food, and healthcare industries, in a transaction valued at €838m ($908m).
“Silgan weighs bid for Gerresheimer – report” was originally created and published by Packaging Gateway, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
